{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T12:02:39Z","timestamp":1793361759656,"version":"4.5.0"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1093\/neuonc\/not150","type":"journal-article","created":{"date-parts":[[2013,12,6]],"date-time":"2013-12-06T01:36:38Z","timestamp":1386293798000},"page":"292-297","source":"Crossref","is-referenced-by-count":125,"title":["Phase II study of everolimus in children and adults with neurofibromatosis type 2 and progressive vestibular schwannomas"],"prefix":"10.1093","volume":"16","author":[{"given":"Matthias A.","family":"Karajannis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genevi\u00e8ve","family":"Legault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari","family":"Hagiwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo G.","family":"Giancotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Filatov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Derman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsivia","family":"Hochman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith D.","family":"Goldberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"Vega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey H.","family":"Wisoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John G.","family":"Golfinos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Merkelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Thomas","family":"Roland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey C.","family":"Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2013,12,4]]},"reference":[{"issue":"3","key":"key\n\t\t\t\t20170508164259_NOT150C1","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/embor.2012.11","article-title":"Merlin: a tumour suppressor with functions at the cell cortex and in the nucleus","volume":"13","author":"Li","year":"2012","journal-title":"EMBO Reports"},{"issue":"4","key":"key\n\t\t\t\t20170508164259_NOT150C2","doi-asserted-by":"crossref","first-page":"951","DOI":"10.2214\/ajr.165.4.7676998","article-title":"Spinal tumors in patients with neurofibromatosis type 2: MR imaging study of frequency, multiplicity, and variety","volume":"165","author":"Mautner","year":"1995","journal-title":"AJR Am J Roentgenol"},{"issue":"1","key":"key\n\t\t\t\t20170508164259_NOT150C3","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1080\/13548506.2010.516363","article-title":"A qualitative study of the impact of living with neurofibromatosis type 2","volume":"16","author":"Patel","year":"2011","journal-title":"Psychol Health Med"},{"issue":"12","key":"key\n\t\t\t\t20170508164259_NOT150C4","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1038\/gim.2012.85","article-title":"Emotional functioning of patients with neurofibromatosis tumor suppressor syndrome","volume":"14","author":"Wang","year":"2012","journal-title":"Genet Med"},{"issue":"16","key":"key\n\t\t\t\t20170508164259_NOT150C5","doi-asserted-by":"crossref","first-page":"5032","DOI":"10.1158\/1078-0432.CCR-08-3011","article-title":"Consensus recommendations to accelerate clinical trials for neurofibromatosis type 2","volume":"15","author":"Evans","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"3","key":"key\n\t\t\t\t20170508164259_NOT150C6","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.cell.2006.01.016","article-title":"TOR signaling in growth and metabolism","volume":"124","author":"Wullschleger","year":"2006","journal-title":"Cell"},{"issue":"1","key":"key\n\t\t\t\t20170508164259_NOT150C7","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/nrm3025","article-title":"mTOR: from growth signal integration to cancer, diabetes and ageing","volume":"12","author":"Zoncu","year":"2011","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"15","key":"key\n\t\t\t\t20170508164259_NOT150C8","doi-asserted-by":"crossref","first-page":"4235","DOI":"10.1128\/MCB.01578-08","article-title":"Loss of the tumor suppressor gene NF2, encoding merlin, constitutively activates integrin-dependent mTORC1 signaling","volume":"29","author":"Lopez-Lago","year":"2009","journal-title":"Mol Cell Biol"},{"issue":"15","key":"key\n\t\t\t\t20170508164259_NOT150C9","doi-asserted-by":"crossref","first-page":"4250","DOI":"10.1128\/MCB.01581-08","article-title":"NF2\/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth","volume":"29","author":"James","year":"2009","journal-title":"Mol Cell Biol"},{"issue":"5","key":"key\n\t\t\t\t20170508164259_NOT150C10","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1158\/1078-0432.CCR-08-2057","article-title":"mTOR inhibitor RAD001 (everolimus) has antiangiogenic\/vascular properties distinct from a VEGFR tyrosine kinase inhibitor","volume":"15","author":"Lane","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"4","key":"key\n\t\t\t\t20170508164259_NOT150C11","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1056\/NEJMoa0902579","article-title":"Hearing improvement after bevacizumab in patients with neurofibromatosis type 2","volume":"361","author":"Plotkin","year":"2009","journal-title":"N Engl J Med"},{"issue":"9637","key":"key\n\t\t\t\t20170508164259_NOT150C12","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","article-title":"Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial","volume":"372","author":"Motzer","year":"2008","journal-title":"Lancet"},{"issue":"19","key":"key\n\t\t\t\t20170508164259_NOT150C13","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1056\/NEJMoa1001671","article-title":"Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis","volume":"363","author":"Krueger","year":"2010","journal-title":"N Engl J Med"},{"issue":"9869","key":"key\n\t\t\t\t20170508164259_NOT150C14","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0140-6736(12)61767-X","article-title":"Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"381","author":"Bissler","year":"2013","journal-title":"Lancet"},{"issue":"6","key":"key\n\t\t\t\t20170508164259_NOT150C15","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1009290","article-title":"Everolimus for advanced pancreatic neuroendocrine tumors","volume":"364","author":"Yao","year":"2011","journal-title":"N Engl J Med"},{"issue":"2","key":"key\n\t\t\t\t20170508164259_NOT150C16","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2165\/00003088-200443020-00002","article-title":"Clinical pharmacokinetics of everolimus","volume":"43","author":"Kirchner","year":"2004","journal-title":"Clin Pharmacokinet"},{"issue":"10 Suppl","key":"key\n\t\t\t\t20170508164259_NOT150C17","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1002\/cncr.24239","article-title":"Targeting mTOR in renal cell carcinoma","volume":"115","author":"Hudes","year":"2009","journal-title":"Cancer."},{"issue":"3","key":"key\n\t\t\t\t20170508164259_NOT150C18","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1586\/erm.09.8","article-title":"mTOR in renal cell cancer: modulator of tumor biology and therapeutic target","volume":"9","author":"Wysocki","year":"2009","journal-title":"Expert Rev Mol Diagn"},{"issue":"30","key":"key\n\t\t\t\t20170508164259_NOT150C19","doi-asserted-by":"crossref","first-page":"4806","DOI":"10.1200\/JCO.2007.11.4017","article-title":"Phase I study of everolimus in pediatric patients with refractory solid tumors","volume":"25","author":"Fouladi","year":"2007","journal-title":"J Clin Oncol"},{"issue":"4","key":"key\n\t\t\t\t20170508164259_NOT150C20","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1097\/00129492-200606000-00018","article-title":"The natural history of vestibular schwannoma","volume":"27","author":"Stangerup","year":"2006","journal-title":"Otol Neurotol"},{"issue":"1","key":"key\n\t\t\t\t20170508164259_NOT150C21","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s11060-009-9867-7","article-title":"Suggested response criteria for phase II antitumor drug studies for neurofibromatosis type 2 related vestibular schwannoma","volume":"93","author":"Plotkin","year":"2009","journal-title":"J Neurooncol"},{"issue":"1","key":"key\n\t\t\t\t20170508164259_NOT150C22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for phase II clinical trials","volume":"10","author":"Simon","year":"1989","journal-title":"Control Clin Trials"},{"issue":"1","key":"key\n\t\t\t\t20170508164259_NOT150C23","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1002\/ajmg.a.34359","article-title":"Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2","volume":"158A","author":"Blakeley","year":"2012","journal-title":"Am J Med Genet A"},{"issue":"6","key":"key\n\t\t\t\t20170508164259_NOT150C24","first-page":"1314","volume":"62","author":"Harris","year":"2008","journal-title":"Three-dimensional volumetrics for tracking vestibular schwannoma growth in neurofibromatosis type II. Neurosurgery"},{"issue":"1","key":"key\n\t\t\t\t20170508164259_NOT150C25","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1097\/00129492-200601000-00020","article-title":"Using audiometric thresholds and word recognition in a treatment study","volume":"27","author":"Halpin","year":"2006","journal-title":"Otol Neurotol"},{"issue":"3","key":"key\n\t\t\t\t20170508164259_NOT150C26","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1044\/jshr.2103.507","article-title":"Speech-discrimination scores modeled as a binomial variable","volume":"21","author":"Thornton","year":"1978","journal-title":"J Speech Hear Res"},{"issue":"9","key":"key\n\t\t\t\t20170508164259_NOT150C27","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1093\/neuonc\/nos146","article-title":"Phase II trial of lapatinib in adult and pediatric patients with neurofibromatosis type 2 and progressive vestibular schwannomas","volume":"14","author":"Karajannis","year":"2012","journal-title":"Neuro Oncol"},{"issue":"5","key":"key\n\t\t\t\t20170508164259_NOT150C28","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1158\/1541-7786.MCR-11-0425-T","article-title":"Regulation of mTOR complex 2 signaling in neurofibromatosis 2\u2013deficient target cell types","volume":"10","author":"James","year":"2012","journal-title":"Mol Cancer Res"},{"issue":"6035","key":"key\n\t\t\t\t20170508164259_NOT150C29","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1126\/science.1199498","article-title":"The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling","volume":"332","author":"Hsu","year":"2011","journal-title":"Science"},{"issue":"6035","key":"key\n\t\t\t\t20170508164259_NOT150C30","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1126\/science.1199484","article-title":"Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling","volume":"332","author":"Yu","year":"2011","journal-title":"Science"},{"issue":"5","key":"key\n\t\t\t\t20170508164259_NOT150C31","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1097\/00129492-200409000-00027","article-title":"Vestibular schwannoma growth rates in neurofibromatosis type 2 natural history consortium subjects","volume":"25","author":"Slattery","year":"2004","journal-title":"Otol Neurotol"},{"issue":"1","key":"key\n\t\t\t\t20170508164259_NOT150C32","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3171\/jns.2005.103.1.0059","article-title":"Systematic review of the natural history of vestibular schwannoma","volume":"103","author":"Yoshimoto","year":"2005","journal-title":"J Neurosurg"},{"issue":"1","key":"key\n\t\t\t\t20170508164259_NOT150C33","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3171\/2012.3.JNS111649","article-title":"Long-term natural history of neurofibromatosis type 2\u2013associated intracranial tumors","volume":"117","author":"Dirks","year":"2012","journal-title":"J Neurosurg"}],"container-title":["Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/16\/2\/292\/16664750\/not150.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,18]],"date-time":"2022-03-18T22:55:24Z","timestamp":1647644124000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-lookup\/doi\/10.1093\/neuonc\/not150"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12,4]]},"references-count":33,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2013,12,4]]},"published-print":{"date-parts":[[2014,2]]}},"URL":"https:\/\/doi.org\/10.1093\/neuonc\/not150","relation":{},"ISSN":["1523-5866","1522-8517"],"issn-type":[{"value":"1523-5866","type":"electronic"},{"value":"1522-8517","type":"print"}],"subject":[],"published":{"date-parts":[[2013,12,4]]}}}